SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft.The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is seeing intense retail and institutional focus driven by its massive IPO, index inclusion mandates that force passive funds to buy despite valuation concerns, and bold claims regarding future trillion-dollar revenue potential. The community remains deeply divided, with bulls betting on SpaceX's dominant role in the future space economy, while skeptics view the current valuation as an extreme bubble fueled by hype and lack of fundamental profitability.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to heightened investor anticipation surrounding Greenland's rare earth sector and reports of Japan dispatching an official delegation to evaluate extraction opportunities in the region. The community is actively discussing the potential for a technical breakout, the strategic importance of the Tanbreez deposit, and the status of project infrastructure updates.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing intense debate among retail investors, with sentiment split between bearish frustration over its lackluster price action and bullish accumulation driven by its dominant global market position and advertising growth. The stock remains a focal point for the community due to ongoing institutional buying interest that contrasts sharply with the vocal skepticism of retail traders who are questioning the stock's recent performance compared to broader market trends.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as the community highlights the publication of robust Phase 3 trial data in The Lancet Oncology, fueling discussions around its potential as a practice-changing prostate cancer treatment. Investors are closely monitoring upcoming milestones, including the start of a Phase 3 trial for NSCLC and the anticipation of a strategic buyout or partnership, while many actively accumulate shares on pullbacks to position for expected future value.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing intense trading activity as its rapid, parabolic ascent toward the $2,000 level triggers a fierce standoff between bullish momentum chasers and bears betting on an inevitable correction. Community conversation is dominated by debates over AI-driven memory demand versus fears of an unsustainable bubble, with many traders actively monitoring geopolitical news and potential stock splits as the next major catalysts.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing high volatility as investors weigh a wave of overwhelmingly positive R2 test-drive reviews against broader market anxiety and skepticism regarding the company's production execution. While the community remains deeply divided between long-term bulls highlighting the R2 as a definitive Tesla competitor and vocal bears focused on cash burn and thin trading volumes, the primary catalyst remains the highly anticipated commercial rollout of the new SUV platform.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is generating significant momentum as investors anticipate a major rerating driven by its expanding defense contracts and position within the space infrastructure sector. Community discussion is heavily focused on the company's potential to capitalize on the orbital AI supercycle and upcoming SpaceX-related market activity, fueling bullish sentiment despite concerns over historical volatility and management execution.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is facing intense volatility as the market anticipates the upcoming SpaceX IPO, with community members heavily debating whether the stock's recent sharp decline represents a forced shakeout or a rational correction due to the loss of its 'pre-IPO scarcity premium.' Despite frustration over the fund's lack of transparency and recent share dilution, many investors are staying patient, betting that exposure to additional high-profile assets like Anthropic and OpenAI will drive a strong rebound post-IPO.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for the investment community following positive Phase 3 results for its in vivo gene-editing therapy, Lonvo-z, which has effectively de-risked its platform and signaled a clear path toward commercialization. Investors are actively debating the significance of the companys recent stock offering and the potential for a short squeeze, while highlighting the transformative HAE market opportunity and sustained institutional interest despite broader sector volatility.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to positive Phase 1 clinical data for subcutaneous Briumvi, which suggests potential for at-home administration and expansion into myasthenia gravis treatment. Investors are actively discussing the stock's buyout potential and market share growth, while closely monitoring upcoming institutional fireside chats for further catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exide sees marginal rise in Q4 net profit

Kolkata: Exide Industries reported a marginal rise in Q4 net profit to Rs 312 crore from Rs 255 crore a year ago, while revenue increased from Rs 4,15.

Best Battery Sector Stocks in India for 2026 Investment Guide

Battery sector stocks in India guide: battery sector growth via electric vehicles, with insights on Exide Industries and HBL Engineering for smart investing decisions.

Brief India: US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! and more

In this briefing: US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 1. US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! On April 2, 2026, a bipartisan group of US lawmakers introduced H.R. 8170, the Multilateral Alignment of Technology Controls on Hardware Act, or the MATCH Act. Three weeks later, on April 22, the House Foreign Affairs Committee advanced it in what lawmakers called ”the largest significant export control mark-up in the history of Congress.” If enacted, the immersion DUV ban will deal a serious blow to China's semiconductor ambitions in the medium term. It will also greatly accelerate Chinese efforts to develop their own... 2. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 3.

Brief India: Exencial Industry Tidings - 27-04-2026 and more

In this briefing: Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 1. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 2. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev.

Brief India: APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear and more

In this briefing: APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 Primer: Zen Technologies (ZEN IN) - Apr 2026 1. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev. Eisai’s Phase 3 trial evaluating Lenvima in RCC did not meet primary endpoints. Celltrion started patient dosing for three of its novel ADC-based anticancer drug candidates. Cochlear has reduced FY26 underlying net profit guidance to A$290–330M from A$435–460M. 2.

Exide Industries Ltd. engages in the provision of manufacturing storage batteries. It operates through the India and Overseas geographical segment. The company was founded in 1946 and is headquartered in Kolkata, India.

Current Price	395.00
Prev Close	392.95
Open	395.50
Dividend Yield	0.69%
50-Day Moving Average	353.00
Beta	0.02
Avg. Volume	4.8M
PE Ratio	39.01

52-Week High	431.00
52-Week Low	287.00
Market Capitalization	333.11B
EPS (Annual)	10.05
Price to Book	2.26
Revenue Per Employee	8.7M

EXIDEIND.NSEExide Industries Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EXIDEIND.NSE News